Compare Stocks: FTH, TLX, ELVN, and AMLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$33.15 -1.5%	$26.31	$10.83 ▼ $41.14	$3.75B	-0.13	3.71 million shs	1.83 million shs
ELVN Enliven Therapeutics	$53.36 -2.0%	$56.53	$14.78 ▼ $62.32	$3.99B	0.3	854,093 shs	866,955 shs
FTH Sensei Biotherapeutics	$35.37 -9.5%	$31.81	$7.45 ▼ $42.14	$1.01B	-0.28	289,783 shs	209,307 shs
TLX Telix Pharmaceuticals	$12.83 +8.9%	$11.25	$6.28 ▼ $13.11	$4.00B	-0.17	227,278 shs	1.08 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-1.46%	-2.15%	+53.26%	+117.38%	+179.75%
ELVN Enliven Therapeutics	-1.97%	-10.12%	-9.28%	+18.95%	+188.43%
FTH Sensei Biotherapeutics	-9.52%	-9.77%	+9.37%	+112.43%	+3,536,999,900.00%
TLX Telix Pharmaceuticals	+8.91%	+7.10%	+8.54%	+29.07%	+34.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$33.15 -1.5%	$26.31	$10.83 ▼ $41.14	$3.75B	-0.13	3.71 million shs	1.83 million shs
ELVN Enliven Therapeutics	$53.36 -2.0%	$56.53	$14.78 ▼ $62.32	$3.99B	0.3	854,093 shs	866,955 shs
FTH Sensei Biotherapeutics	$35.37 -9.5%	$31.81	$7.45 ▼ $42.14	$1.01B	-0.28	289,783 shs	209,307 shs
TLX Telix Pharmaceuticals	$12.83 +8.9%	$11.25	$6.28 ▼ $13.11	$4.00B	-0.17	227,278 shs	1.08 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-1.46%	-2.15%	+53.26%	+117.38%	+179.75%
ELVN Enliven Therapeutics	-1.97%	-10.12%	-9.28%	+18.95%	+188.43%
FTH Sensei Biotherapeutics	-9.52%	-9.77%	+9.37%	+112.43%	+3,536,999,900.00%
TLX Telix Pharmaceuticals	+8.91%	+7.10%	+8.54%	+29.07%	+34.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	17.22% Upside
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	40.55% Upside
FTH Sensei Biotherapeutics	2.86	Moderate Buy	$55.00	55.50% Upside
TLX Telix Pharmaceuticals	2.86	Moderate Buy	$20.40	59.00% Upside

Current Analyst Ratings Breakdown

Latest FTH, TLX, ELVN, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/14/2026	FTH Sensei Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/9/2026	FTH Sensei Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	42.28	N/A	N/A	$2.78 per share	11.92
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
TLX Telix Pharmaceuticals	$803.79M	5.42	$0.05 per share	279.39	$1.23 per share	10.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	213.83	N/A	N/A	N/A	N/A	N/A

Latest FTH, TLX, ELVN, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
ELVN Enliven Therapeutics	N/A	64.07	64.07
FTH Sensei Biotherapeutics	N/A	19.69	19.69
TLX Telix Pharmaceuticals	1.16	2.01	1.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ELVN Enliven Therapeutics	95.08%
FTH Sensei Biotherapeutics	10.50%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
ELVN Enliven Therapeutics	3.00%
FTH Sensei Biotherapeutics	7.00%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A

FTH, TLX, ELVN, and AMLX Headlines

Recent News About These Companies

Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Up 10.22%

3 hours ago | aaii.comA

Telix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from Wedbush

September 16 at 1:36 AM | americanbankingnews.com

ASX biotech expands diagnostics portfolio after FDA approval

September 15 at 10:49 PM | morningstar.com.auM

Are Telix shares a buy after its big US FDA news?

September 15 at 10:49 PM | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Earns Buy Rating from HC Wainwright

September 15 at 10:05 AM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year High - Time to Buy?

September 15 at 9:39 AM | marketbeat.com

Telix Pharmaceuticals Receives FDA Approval for Brain Cancer Imaging Drug Pixclara

September 14 at 2:15 PM | finance.yahoo.com

Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14 at 2:15 PM | seekingalpha.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What Happened

September 14 at 10:39 AM | marketbeat.com

FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug

September 14 at 9:50 AM | benzinga.com

FDA green light for Telix’s brain cancer imaging drug Pixclara

September 14 at 9:15 AM | thepharmaletter.comT

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

September 14 at 9:15 AM | finance.yahoo.com

Telix's Pixclara Wins FDA Approval For Glioma Imaging In Adults And Children

September 14 at 9:15 AM | rttnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from Wedbush

September 14 at 8:59 AM | marketbeat.com

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

September 14 at 6:30 AM | globenewswire.com

Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

September 13 at 11:04 PM | fool.com.au

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

September 13 at 11:04 PM | finance.yahoo.com

Why are Telix Pharmaceuticals shares charging higher today?

September 13 at 11:04 PM | msn.com

FDA approves Telix brain cancer imaging drug Pixclara

September 13 at 11:04 PM | seekingalpha.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Still a Buy?

September 11, 2026 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Sets New 1-Year High - What's Next?

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, TLX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$33.15 -0.49 (-1.46%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$33.33 +0.18 (+0.53%)

As of 07:22 AM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Enliven Therapeutics NASDAQ:ELVN

$53.36 -1.07 (-1.97%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$53.38 +0.02 (+0.03%)

As of 04:55 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Sensei Biotherapeutics NASDAQ:FTH

$35.37 -3.72 (-9.52%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$35.86 +0.49 (+1.37%)

As of 07:00 AM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Telix Pharmaceuticals NASDAQ:TLX

$12.83 +1.05 (+8.91%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$12.36 -0.47 (-3.62%)

As of 07:23 AM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, TLX, ELVN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, TLX, ELVN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, TLX, ELVN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, TLX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Enliven Therapeutics NASDAQ:ELVN

Sensei Biotherapeutics NASDAQ:FTH

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, TLX, ELVN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, TLX, ELVN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, TLX, ELVN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, TLX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Enliven Therapeutics NASDAQ:ELVN

Sensei Biotherapeutics NASDAQ:FTH

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools